DRKS00007841
Completed
Phase 1
Individually tailored E-health interventions for primary care patients with problematic alcohol use and co-occurring depressive symptoms (Phase 1) - ITE (Phase 1)
niversitätsmedizin Greifswald, Institut für Sozialmedizin und Prävention0 sites34 target enrollmentAugust 31, 2015
ConditionsAt-risk alcohol consumption (average daily intake of alcohol > 12g for women / >24g men or >= one occasion a month with >= 4 alcoholic drinks for women / >= 5 drinks for men). At-risk alcohol consumption is considered as a risk factor for Harmful Alcohol use (ICD-10 F10.1), Alcohol Dependence Syndrome (ICD-10 F10.2), and other alcohol attributable disease. subsyndromal depressive symptoms, majordepression (ICD-10 F32) or dysthymia (ICD-10 F34.1)F10.1: Harmful use of alcoholF10.2: Alcohol dependence syndromF10.1F10.2F32F34.1Depressive episodeDysthymia
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- At-risk alcohol consumption (average daily intake of alcohol > 12g for women / >24g men or >= one occasion a month with >= 4 alcoholic drinks for women / >= 5 drinks for men). At-risk alcohol consumption is considered as a risk factor for Harmful Alcohol use (ICD-10 F10.1), Alcohol Dependence Syndrome (ICD-10 F10.2), and other alcohol attributable disease. subsyndromal depressive symptoms, majordepression (ICD-10 F32) or dysthymia (ICD-10 F34.1)F10.1: Harmful use of alcoholF10.2: Alcohol dependence syndrom
- Sponsor
- niversitätsmedizin Greifswald, Institut für Sozialmedizin und Prävention
- Enrollment
- 34
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) At\-risk alcohol consumption (average daily alcohol use of \>12g women / 24g men or \>\= one occasion a month with \>\= 4 alcoholic drinks for women / \>\= 5 drinks for men)
- •2\) subsyndromal depressive symptoms, major depression or dysthymia in the past 12 months.
Exclusion Criteria
- •1\. Severe episode of major depression within the past 12 month and depressive symptoms in the past 2 weeks;
- •2\. Moderate/severe alcohol use disorder according to DSM\-5;
- •3\. Illiteracy, cognitive impairment;
- •4\. Currently in psychotherapeutic treatment
- •5\. Acute or severe illness, which did not allow participation in the study;
- •6\. less than weekly use of the Internet and no accessibility by cell phone.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Individually tailored E-health interventions for primary care patients with problematic alcohol use and co-occurring depressive symptoms: Phase IIa - proof of concept studyAt-risk alcohol consumption (average daily intake of alcohol > 12g for women / >24gmen or >= one occasion a month with >= 4 alcoholic drinks for women / >= 5 drinks for men).At-risk alcohol consumption is considered as a risk factor for Harmful Alcohol use (ICD-10F10.1), Alcohol Dependence Syndrome (ICD-10 F10.2), and other alcohol attributable disease.subsyndromal depressive symptoms, majordepression (ICD-10 F32) or dysthymia (ICD-10 F34.1)F10.1: Harmful use of alcoholF10.2: Alcohol dependence syndromF10.1F10.2F32F34.1Depressive episodeDysthymiaDRKS00011635niversitätsmedizin Greifswald, Institut für Sozialmedizin und Prävention141
Recruiting
N/A
Tailored cognitive-behavioral E-health care in patients with rheumatoid arthritisrheumatic diseaserheumatoid arthritis10023213NL-OMON32692niversitair Medisch Centrum Sint Radboud600
Completed
N/A
Towards the development of a personalised E-Health intervention for use in community pharmacies to analyse and improve medication non-adherence in people with type 2 diabetes mellitus, who are non-adherent to oral blood glucose and/or blood pressure lowering drugs.NL-OMON55758Vrije Universiteit Medisch Centrum150
Completed
N/A
Tailored cognitive-behavioral E-health care in patients with rheumatoid arthritis.Rheumatoid arthritisReumatoïde artritisNL-OMON28299Radboud University Nijmegen Medical Centre130
Recruiting
N/A
Tailored cognitive-behavioral E-health care in patients with psoriasis.PsoriasisNL-OMON25268Radboud University Nijmegen Medical Center130